Presage Biosciences, a US-based developer of drugs for cancers in animals, has sold a minority stake worth $8m to peer Celgene. Celgene is also investing an initial $5m to help pay for Presage’s clinical trials with more available if performance targets are hit. Thomas Daniel, president of research and early development at Celgene, said: “Drug…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
